Caveolin-1 in renal disease

  title={Caveolin-1 in renal disease},
  author={S. Chand},
Renal disease is a major global public health issue that affects 10% of the general population with premature morbidity and mortality related to cardiovascular disease and infection. Interstitial fibrosis is a common hallmark of progressive kidney dysfunction. There remains a stubborn discrepancy in identifying which patients suffer adverse events because of their disease or resulting treatment. Investigation in patient genome variation may explain this discrepancy. Caveolin-1 is the… Expand


Caveolin-1 single-nucleotide polymorphism and arterial stiffness in non-dialysis chronic kidney disease.
  • S. Chand, N. Edwards, +10 authors R. Borrows
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2016
A replicated study suggests potential utility of the studied CAV1 SNP as a genetic biomarker in CKD and a role forCAV1 in the development of arteriosclerosis in this setting. Expand
Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis
Cav-1 was able to suppress TGF-β1–induced ECM production in cultured fibroblasts through the regulation of the c-Jun N-terminal kinase (JNK) pathway and suggests a novel therapeutic target for patients with pulmonary fibrosis. Expand
Contribution of genetics and epigenetics to progression of kidney fibrosis.
  • B. Tampe, M. Zeisberg
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2014
Recent insights provided by genome-wide association studies (GWASs), gene-linkage studies and epigenome analysis are reviewed, providing evidence that genetic polymorphisms and epigenetic variations determine the individual susceptibility of patients to develop chronic progressive kidney disease. Expand
Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease
Caveolin-1 downregulation in leucocytes contributes to fibrotic lung disease, highlighting caveolin- 1 as a promising therapeutic target in scleroderma. Expand
Caveolin-1 Single Nucleotide Polymorphism in Antineutrophil Cytoplasmic Antibody Associated Vasculitis
The presence of a CC genotype in Birmingham is associated with protection from adverse outcomes of immunosuppression treated AAV, and this findings are worthy of further study in larger cohorts. Expand
Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis.
Caveolin 1 appears to participate in the pathogenesis of tissue fibrosis in SSc, and restoration of caveolin 1 function by treatment with a cell-permeable peptide corresponding to the CAV1 scaffolding domain may be a novel therapeutic approach in S sc. Expand
The significance of caveolae in the glomeruli in glomerular disease
The expression of Cav-1 was significantly increased in the glomeruli of patients with glomerular disease, and it was related to urinary albumin excretion. Expand
Donor caveolin 1 (CAV1) genetic polymorphism influences graft function after renal transplantation
Genotyping of CAV1 may be relevant to identify patients at risk of adverse renal transplant outcome, and significantly developed more interstitial fibrosis lesions on systematic biopsies performed 3 months post-transplantation. Expand
Arterial disease in chronic kidney disease
End stage renal disease is associated with a very high risk of premature cardiovascular death and morbidity and recent work has highlighted the importance of aldosterone and disordered bone mineral metabolism. Expand
Pharmacogenetic Association of NOS3 Variants with Cardiovascular Disease in Patients with Hypertension: The GenHAT Study
It is suggested that NOS3 variants may potentially provide useful clinical information with respect to treatment decisions in the future and significant pharmacogenetic effects for stroke and all cause mortality were observed. Expand